SCHEMBL10302192

SCHEMBL10302192

C=Cc1ccc(OCc2ccc(-c3ccc(OCC)c(F)c3F)cc2)c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ TACR2 P21452 1/20 0.36
▸ GABRA1 P14867 3/20 0.36
▸ GABRB2 P47870 3/20 0.36
▸ FGFR2 P21802 2/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ NTSR1 P30989 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ HTR1A P08908 2/20 0.35
▸ ADRA1D P25100 2/20 0.35
▸ ADRA1A P35348 2/20 0.35
▸ ADRA1B P35368 2/20 0.35
▸ FFAR4 Q5NUL3 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10303361 0.92 FGFR2 (0.40) KDM4EMAPTALDH1A1HPGDGABRA1
SCHEMBL12994781 0.91 MRGPRX4 (0.40) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL12836822 0.91 FGFR2 (0.39) KDM4EMAPTALDH1A1HPGDGABRA1
SCHEMBL12740940 0.88 TACR2 (0.42) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL12736487 0.88 TACR2 (0.42) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL1243355 0.88 HTR1A (0.42) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL10302193 0.86 FFAR4 (0.36) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL10302303 0.86 FFAR1 (0.39) KDM4EMAPTGABRA1GABRB2FGFR2
SCHEMBL10302244 0.86 FFAR1 (0.39) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL10301922 0.85 GABRA1 (0.36) GABRA1GABRB2FGFR2FGFR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8216489-B2 Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-07-10 — — US disclosed
US-8216489-B2 Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-07-10 — — US disclosed
US-20110037024-A1 THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-02-17 — — US disclosed
US-20110037024-A1 THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-02-17 — — US disclosed
EP-2266941-A1 TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE Chisso Corporation (JP) 2010-12-29 — — EP disclosed
WO-2009125668-A1 TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE チッソ株式会社 (JP) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110037024-A1 THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE LEF1, LAS1L, L3MBTL3 KDM4E 2638/4885MAPT 836/4885ALDH1A1 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback